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Abstract
Background: The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia
(CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological
malignancies including CLL. Binding of the pro-survival chemokine CXCL12 with its cognate receptor CXCR4
induces cell migration. CXCL12/CXCR4 signaling axis promotes cell survival and proliferation and may
contribute to the tropism of leukemia cells towards lymphoid tissues and bone marrow. Therefore, we
hypothesized that targeting CXCR4 with an IgG1 antibody, PF-06747143, may constitute an effective
therapeutic approach for CLL.
Methods: Patient-derived primary CLL-B cells were assessed for cytotoxicity in an in vitro model of CLL
microenvironment. PF-06747143 was analyzed for cell death induction and for its potential to interfere with
the chemokine CXCL12-induced mechanisms, including migration and F-actin polymerization. PF-06747143
in vivo efficacy was determined in a CLL murine xenograft tumor model.
Results: PF-06747143, a novel-humanized IgG1 CXCR4 antagonist antibody, induced cell death of patient-derived
primary CLL-B cells, in presence or absence of stromal cells. Moreover, cell death induction by the antibody was
independent of CLL high-risk prognostic markers. The cell death mechanism was dependent on CXCR4 expression,
required antibody bivalency, involved reactive oxygen species production, and did not require caspase activation, all
characteristics reminiscent of programmed cell death (PCD). PF-06747143 also induced potent B-CLL cytotoxicity via
Fc-driven antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity activity
(CDC). PF-06747143 had significant combinatorial effect with standard of care (SOC) agents in B-CLL treatment,
including rituximab, fludarabine (F-ara-A), ibrutinib, and bendamustine. In a CLL xenograft model, PF-06747143
decreased tumor burden and improved survival as a monotherapy, and in combination with bendamustine.
Conclusions: We show evidence that PF-06747143 has biological activity in CLL primary cells, supporting a rationale
for evaluation of PF-06747143 for the treatment of CLL patients.
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Background
CXCR4 (chemokine C-X-C motif receptor 4), also known
as CD184, is a chemokine G protein coupled receptor [1],
expressed in different cell types, including normal B cells
[2–6]. CXCR4 is overexpressed in a variety of cancers in-
cluding chronic lymphocytic leukemia (CLL), acute mye-
loid leukemia (AML), myeloma, lymphomas, and solid
tumors [7]. CXCL12 (chemokine C-X-C motif ligand 12),
also known as stromal cell-derived factor 1 (SDF-1), is
CXCR4 sole ligand. It is a homeostatic chemokine [8],
highly expressed in the lymph nodes, bone marrow (BM),
liver, and lung [9]. CXCL12 regulates hematopoietic cell
trafficking and their homing to the BM [5]. Chemotaxis
driven by CXCR4 and CXCL12 interactions has been
shown to control various biological functions including
cell adhesion, migration, and invasion [10].
CLL is the most prevalent adult leukemia and is charac-
terized by accumulation of dysfunctional B-lymphocytes
in the lymph nodes and BM [11]. Stromal cells secrete
CXCL12 and promote B-cell progenitors and CLL cell
survival through CXCR4 signaling [8, 12, 13]. Thus, acti-
vation of the CXCL12/CXCR4 axis plays an important
role in stromal cell-dependent resistance to therapy in
CLL patients, including cytotoxic drugs [4] or steroids
[14], thereby promoting minimal residual disease [15].
These observations support the rationale for targeting
CXCR4 for the treatment of CLL.
In the last decade, a number of agents targeting CXCR4
have been developed. These include small molecules, pep-
tides, and monoclonal antibodies. The role of CXCR4 in
hematopoietic stem cell (HSC) retention and trafficking led
to the development of agents used for HSC mobilization.
AMD3100 (Plerixafor), a small molecule inhibitor of
CXCR4, was approved for mobilization of HSCs prior to
autologous transplantation; however, this compound has
limited application for sustained treatment due to toxicity
[16, 17]. BL-8040 (BKT140), a peptide inhibitor of CXCR4,
has robust cell mobilization capacity [18, 19], similarly to
other CXCR4-specific antagonist peptides (T-140, TN-
14003, TC-14012), which were shown to inhibit CXCR4-
CXCL12 signaling in CLL-B cells [4]. However, these pep-
tides show limited in vivo exposures. Recently, two CXCR4
human IgG4 antagonist antibodies, ulocuplumab [20–22]
and LY2624587 [23], were described. Ulocuplumab is cur-
rently in phase 1 clinical studies, and it was shown to have
prolonged pharmacokinetic exposure compared to small
molecules or peptide inhibitors [20–22].
PF-06747143 is a novel and potentially first in class hu-
manized IgG1 anti-CXCR4 antibody that recently entered
into clinical studies (NCT02954653). Here, we show that
it potently binds to CXCR4 and inhibits CXCL12-driven
calcium flux. Moreover, it induces cell death in malignant
CLL-B cells via two main mechanisms of action: (1)
bivalency-dependent mechanism, involving generation of
reactive oxygen species (ROS) and independent of cas-
pases and (2) Fc region-driven cytotoxicity, including
complement-dependent cytotoxicity (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC) activity. Im-
portantly, we show that PF-06747143 triggers cell death in
B-CLL patient-derived primary leukemia cells, in spite of
the presence of stromal cells, mimicking the leukemia
microenvironment in vitro. The antibody also synergizes
with conventional CLL treatment agents such as benda-
mustine, rituximab, fludarabine (F-ara-A), and ibrutinib,
significantly improving their cytotoxicity in combination.
Furthermore, we show that PF-06747143 inhibits tumor
burden and improves survival as a monotherapy or in
combination with bendamustine, in a CLL xenograft
tumor model. Based on these unique mechanisms of ac-
tion, PF-06747143 has a promising therapeutic potential
in CLL patients and other hematological malignancies
dependent on the CXCR4 axis.
Methods
Isolation of PBMCs from CLL patients
The CLL-B cells were collected from blood samples at the
Moores-UCSD Cancer Center in compliance with the Dec-
laration of Helsinki and after approval of the UC San Diego
Institutional Review Board (IRB) [24].Peripheral blood
mononuclear cells (PBMC) from CLL patients were iso-
lated using Ficoll-Hypaque gradient density centrifugation
(Cat# 17-1440-03, GE Healthcare Life Science). For caspase
activation assays, the CLL-B cells were purified by positive
selection using Dynabeads CD19 pan B (Cat# 11143D, Invi-
trogen) and DETACHaBEAD CD19 (Cat# 12506D, Invitro-
gen) according to the manufacturer’s protocol. For the
other assays, fresh or frozen PBMCs were used and cells
were stained with CD19/CD5 antibodies for detection of
double positive CLL-B cells.
CLL-B cells co-culture to mimic CLL microenvironment
Primary leukemic cells from CLL patients were cultured
in RPMI supplemented with 10% heat-inactivated FBS
(fetal bovine serum, Catalog # FB-02, Omega Scientific,
Tarzana, CA) and 1% antibiotic at a density of 3 × 105
cells per milliliter at 37 °C and 5% CO2. The cells were
either cultured in 96-well round bottom plates (Catalog
# 3596, Corning, NY) alone or co-cultured with NK-tert
stromal cells (RIKEN, Yokohama, Japan) at a ratio of
20:1 (CLL: stroma-NK-tert) in RPMI with 1% Penn-
Strep and 10% FBS [25].
CXCR4 expression by flow cytometry
The CXCR4 phenotyping of CLL-B, stroma-NK-tert,
normal B, and T cells was done by flow cytometry using
a 1:50 dilution with rat anti-human CD184 (CXCR4) PE
Mab (Catalog # 551966, clone:2B11, BD Biosciences).
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The isotype control antibody was PE Rat IgG2b, κ (Catalog #
12-4031-83, clone: eB149/10H5, eBioscience).
CXCR4 antibody generation
The parental CXCR4 antagonist antibody, m15, was de-
rived from immunization of Balb/c mice with CHO cells
transfected with human CXCR4. The heavy and light
chain variable domains of m15 were then cloned into
human IgG1 or hinge stabilized IgG4 and light κ back-
bone, to generate chimeric m15-IgG1 and m15-IgG4.
m15 was subsequently humanized by CDR grafting/af-
finity maturation and cloned into human IgG1/κ con-
stant domains to create PF-06747143.
Binding kinetics and affinity
Experiments were performed on a BiacoreTM T200 surface
plasmon resonance biosensor (GE Life Sciences). The
binding to human CXCR4 was determined using human
CXCR4-enriched lipoparticles (Integral Molecular) com-
pared to null particles. Lipoparticles were diluted into
10 mM HEPES, 150 mM NaCl, 1 mg/mL BSA, pH 7.4
buffer to concentrations between 0.015 to 0.04 units/mL
and captured for 5 min onto flow cells. A threefold dilu-
tion series of Fab was evaluated and dissociation was
monitored for 10 min. The data were fit to a 1:1 Langmuir
with mass transport model using Biacore T200 Evaluation
Software Version 2.0.
PF-06747143 binding to tumor cells by flow cytometry
Cell suspensions (n = 3/group) were stained with 20 μg/
mL of either a human IgG1 ĸ Phycoerthrin (PE)-labeled
antibody (isotype control) (Southern Biotech) or with PF-
06747143 PE-conjugated antibody, labeled using the Site-
Click™ R-PE Kit (Molecular Probes, Life Technologies).
Flow cytometric acquisition and analysis was conducted
using FACS LSRII™ flow cytometer (Beckman Dickinson).
Calcium flux functional assay
The ability of PF-06747143 or m15-IgG1 to inhibit
CXCL12-induced calcium flux was evaluated in human
T cell leukemia Jurkat cells using the Fluo-NW Calcium
assay kit (Life Technologies). Cells were plated in 384-well
plates at 70,000 cells per well in quadruplicates and incu-
bated with m15-IgG1 parent antibody and PF-06747143,
upon stimulation with CXCL12 at 8 nM (EC80) (Invitro-
gen), for 110 min. Calcium flux was then measured for
95 s using a FLIPR Tetra (Molecular Devices).
Cell death
Cell death was evaluated by flow cytometry analysis
using CD19/CD5/Annexin V antibodies [26]. Specific in-
duced cell death (SICD) calculation was used in order to
discriminate the antibody/compound-specific induced
cell death from background or spontaneous cell death
observed in the vehicle-treated groups. The calculation
of % SICD was performed using the following formula:
% SICD = (Compound-induced cell death − Vehicle
spontaneous cell death)/(100 − Vehicle spontaneous cell
death) × 100.
Cell death in combination with CLL standard of care
agents
m15-IgG1 was tested in combination with different stand-
ard of care (SOC) agents currently used for treatment of
CLL. F-ara-A, bendamustine, rituximab, and ibrutinib
were evaluated in combination with 200 nM of m15-IgG1.
CLL-B cells were treated for 48 h at 37 °C either cultured
alone or co-cultured with stroma-NK-tert cells. The com-
bination data and level of synergism was analyzed using
CompuSyn software (ComboSyn, Inc., NJ, USA). The data
derived from this analysis were expressed as combination
index (CI), which offers definition for additive (CI = 1),
synergism (CI < 1), and antagonism (CI > 1) in drug com-
bination [27].
Antibody-dependent cellular cytotoxicity (ADCC) assay
For analysis of ADCC in B-CLL patient primary cells, the
ADCC Reporter Bioassay kit from Promega (Catalog
#G7010) was used, per instructions from the manufacturer.
The ADCC Reporter Bioassay uses engineered Jurkat cells
stably expressing the FcγRIIIa receptor, V158 (high affinity)
variant, and a NFAT (nuclear factor of activated T cells)
pathway response element driving expression of firefly lu-
ciferase as effector cells. The transfected Jurkat cell line was
grown in RPMI containing G-418 sulfate solution (Catalog
# V8091) and hygromycin (Catalog # 10687010, 50 mg/mL
solution). The ADCC buffer (99.5% RPMI 1640 with L-
glutamine and 0.5% super low IgG FBS) was prepared using
RPMI supplemented with super low IgG defined fetal bo-
vine serum (catalog # SH30898, Hyclone). The luciferase
assay system was used as a readout (Catalog # G7940, Pro-
mega). Different concentrations of antibodies IgG1 control,
PF-06747143, rituximab and obinutuzumab were added to
the effector/target cell 1:1 ratio mixtures. A total of 75,000
for effector and target cells were incubated for 6 h at 37 °C
in a humidified CO2 incubator. Following incubation, the
plate was equilibrated to ambient temperature for 15 min.
Bio-Glo™ luciferase assay reagent was added and incubated
at room temperature for 30 min. The luminescence was de-
tected using an Infinite 200 Microplate Reader (Tekan),
and the results are expressed in relative light units (RLU).
ADCC activity of PF-06747143 and m15-IgG1 parent
antibody was evaluated in JVM-13 CLL tumor cell line, in
presence of the NK-92 FcγRIIIA 158V (NK92 158V) cell
line as effector cells (Conkwest). Antibodies were incu-
bated for 4 h, with tumor cells and effector cells (1:10 ra-
tio) (n = 4/group). ToxiLight bioluminescent cytotoxicity
assay (Cat # LT07-117 Lonza) was used to detect cell lysis.
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CDC assay
PF-06747143 was added to CLL-B cells (1 × 106/mL) in
RPMI media with 5% active human serum [28, 29] or
inactivated human serum, which was incubated at 56 °C
for 30 min. The heat-inactivated/normal human serum-
treated cells were incubated for 4 h at 37 °C with in-
creasing concentrations of PF-06747143. Cytotoxicity
was determined by flow cytometry using CD19/CD5/
Annexin V staining. % SICD was calculated according to
the following formula: 100 × (% viable cells with inacti-
vated serum −% viable cells with native serum)/(% viable
cells with inactivated serum).
Inhibition of actin polymerization
Cytoskeletal reorganization (F-actin polymerization) was
evaluated in CLL samples activated by CXCL12 and
treated with PF-06747143 or control agents [4].
Inhibition of migration of cells in a transwell assay
PF-06747143 was assessed for its ability to inhibit
CXCL12-induced chemotaxis in primary CLL-B cells de-
rived from CLL patients using a transwell migration
assay [30].
Caspase activity assay
To evaluate the mechanism of cell death induced by PF-
06747143, CLL-B cells were purified from patient-derived
PBMCs and tested for caspase activation including caspases
3, 8, and 9 using the ApoTarget Caspase Colorimetric
Protease Assay Sampler kit (Cat # KHZ1001, Invitrogen,
Frederick, MD) according to the manufacturer’s instruc-
tions. Z-VAD-FMK, a caspase inhibitor (Cat # G7231,
Promega Corporation), was used as control [31].
Detection of reactive oxygen species (ROS) by flow
cytometry
CLL-B cells were seeded at 2.5 × 105/mL in RPMI media
and treated with antibodies for 4 h at 37 °C and 5% CO2 in
24-well plates. The generation of ROS was detected using
dihydroethidium (HE) staining (Catalog # D1168, Sigma-
Aldrich, St. Louis, MO) as described previously [32]. The
samples were then analyzed by flow cytometry followed by
data analysis using FlowJo software.
In vivo efficacy study
JVM-13 tumor cell line [33, 34], purchased from ATCC,
was stably transfected with the luciferase gene. The cells
were cultured in RPMI media with 10% FBS. To establish
a JVM-13 disseminated model, 1 × 106 cells per mouse
were implanted via tail vein injection in female SCID beige
mice (Charles River). Tumor burden was monitored via
bioluminescence imaging (BLI) (IVISÒ 200) throughout
the study. When the tumor burden (mean BLI) reached
7.2 × 106 photons/s, on day 19, mice were randomly
assigned into four groups and treated with (1) IgG1 nega-
tive control Ab or (2) PF-06747143, dosed subcutaneously
at 10 mg/kg, once a week, for a total of 6 doses; (3) benda-
mustine, dosed intraperitoneally at 30 mg/kg, on days 19
and 20, followed by another 2-day treatment cycle 28 days
later; and (4) combination of PF-06747143 and bendamus-
tine. Mice were euthanized according to the IACUC
guidelines once they developed disease-related symptoms
such as hind leg paralysis.
Statistical analysis
The statistical analysis was carried out using Graph-
Pad Prism software (v. 5.0c; San Diego, CA). The
statistical differences for the mean values were ana-
lyzed using one way ANOVA and are indicated with
*, p < 0.05; **, p < 0.01; ***, p < 0.001; and ****, p <
0.0001. Tumor model survival analysis was per-
formed using Kaplan-Meier followed by a long-rank
(Mantel-Cox) test.
Results
Expression of CXCR4 in CLL, normal B cells, stroma-NK-
tert, leukemia, and lymphoma cell lines
Expression of CXCR4 was evaluated by flow cytometry
in primary B-CLL cells from patients, as well as normal
B, T, and stroma-NK-tert cells. A representative ex-
ample of CXCR4 staining is shown in Fig. 1a. CXCR4
expression was higher in CLL-B cells compared to nor-
mal B and T cells. We then assessed CXCR4 expression
levels in high- and low-risk CLL patient groups. CLL
patients were stratified into high risk (ZAP-70 ≥ 20%,
IgVH ≥ 98% homology) and low risk (ZAP-70 < 20%,
IgVH < 98% homology) based on ZAP-70 expression
and IgVH homology status [35]. The average mean
fluorescence (ΔMFI) for CXCR4 expression in CLL
samples ranged from 263.73 to 2401.7, regardless of
high- or low-risk status. The ΔMFI in high-risk patients
was 1497.23 ± 195.89 and in low-risk patients, it was
1533.73 ± 178.54. Upon comparison between low- and
high-risk CLL patients, no significant difference in
CXCR4 expression levels was observed (p = 0.8601).
Overall, CXCR4 expression was significantly higher in
CLL-B cells as compared to normal B or T cells (10-
and 22-fold, respectively; p < 0.0001) (Fig. 1b). Further-
more, CXCR4 expression in leukemia and lymphoma
cell lines including K562, MEC1, Namalwa, Raji, JeKo-
1, and Jurkat showed a broad range of expression levels,
with ΔMFIs of −2.35, 0.01, 73.41, 526.72, 725.45, and
1358.5, respectively (Additional file 1: Figure S1).
PF-06747143 and the parental m15 antibody bind CXCR4
with high selectivity and affinity
To determine the binding specificity and affinity of PF-
06747143 and its parental antibody m15 to human (h)
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CXCR4, we employed surface plasmon resonance. The
monovalent Fab fragments of each antibody were incu-
bated with hCXCR4-enriched lipoparticles. The apparent
equilibrium dissociation constant (KD) was 0.36 nM for
PF-06747143 and 0.67 nM for the parental antibody, m15,
indicating that both antibodies have potent and compar-
able affinity to hCXCR4 (Table 1). None of the Fabs bound
to lipoparticles lacking hCXCR4 (data not shown). In a
separate experiment, PF-06747143 was fluorescently la-
beled (PF-06747143-PE) and binding to CHO cells ex-
pressing hCXCR4 (CHO-hCXCR4) was compared to
binding to cells transfected with empty vector (CHO-par-
ental). PF-06747143-PE bound specifically to CHO cells
expressing hCXCR4 (CHO-hCXCR4) but not to the
CHO-parental cells (Fig. 2a), demonstrating selective
binding to CXCR4-expressing cells.
PF-06747143 and the parental antibody m15-IgG1 inhibit
CXCL12-induced calcium flux
Calcium flux is triggered upon activation of CXCR4 by its
ligand, CXCL12. We next evaluated the ability of PF-
06747143 and its parental antibody, m15, expressed as a
chimeric human IgG1 antibody (m15-IgG1), to inhibit cal-
cium flux induced by CXCL12. The Jurkat T cell leukemia
line, which expresses high levels of CXCR4 (Additional
file 1: Figure S1), was incubated with CXCL12 (EC80 at
8 nM) to stimulate calcium flux. A titration of PF-
06747143 and m15-IgG1 was performed. Both PF-
06747143 and m15-IgG1 blocked CXCL12-induced
calcium flux in a dose-dependent manner, with similar
IC50s of 1.41 and 1.13 nM, for PF-06747143 and m15-IgG1,
respectively. These results show that both CXCR4 anti-
bodies have potent and comparable CXCL12 antagonistic
activity (Fig. 2b).
Next, we evaluated if bivalency was required for PF-
06747143 to inhibit calcium flux. To this end, a bivalent
form of PF-06747143, which has no constant Fc region
[F(ab’)2], and a monovalent form of the antibody [Fab],
were generated and compared to PF-06747143, which is a
bivalent full-length antibody (PF-06747143 FL). (Additional
file 2: Figure S2). Similar CXCL12-induced calcium flux in-
hibition was observed for all three forms of PF-06747143
tested, indicating that the functional CXCL12 antagonistic
Fig. 1 Expression of CXCR4 receptor in CLL-B, normal B, T, and stroma-NK-tert cells. a CXCR4 expression was assessed by surface staining using
an anti-CXCR4 antibody in CLL-B, normal B, T, and stroma-NK-tert cells. A representative panel is shown. b CXCR4 expression was evaluated by
flow cytometry in CLL patient cells with high-risk and low-risk characteristics (n = 20 per group) and in normal B and T cells obtained from healthy
donors (n = 5 per group). The figure shows the mean fluorescence intensities (MFI) ± standard deviation (SD) of the samples analyzed in duplicate
for CXCR4 expression in each cell type. Statistical significance was determined by using Bonferroni’s correction test for multiple comparison tests,
where *, **, ***, and **** represent p < 0.05; p < 0.01, p < 0.001, and p < 0.0001, respectively
Table 1 Biosensor kinetics and affinity measurements
Clone name ka (1/Ms) kd (1/s) t1/2 (min) KD (nM)
m15 Fab 2.1 × 106 1.4 × 10−3 8.3 0.67
PF-06747143 Fab 8.0 × 105 2.9 × 10−4 40 0.36
Binding affinities of the Fab regions derived from PF-06747143 and its parent
antibody m15 were measured by surface plasmon resonance
ka kinetic association constant, kd kinetic dissociation constant, t1/2 dissociation
half-life, KD equilibrium dissociation constant
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activity is not dependent on bivalent binding or Fc constant
region of the antibody.
The CXCR4 antibody induces cell death in CXCR4-
expressing CLL patient cells
m15-IgG1 was evaluated for its ability to trigger cell
death upon binding to primary CLL-B cells expressing
CXCR4 or to the MEC1 (CLL) cell line, which has no
detectable CXCR4 expression (ΔMFI = 0.01) (Fig. 3a).
Cells were incubated with increasing concentrations of
m15-IgG1 or control IgG1 antibody and analyzed for
cell death using flow cytometry. CLL-B cells underwent
cell death upon treatment with m15-IgG1 (2–2000 nM)
in a dose-dependent manner, while MEC1 cells did not
show evidence of cell death, even in presence of high
concentrations of the antibody (Fig. 3b), indicating that
the CXCR4 antibody cell death is CXCR4 expression
dependent.
The CXCR4 antibody induces cell death in spite of the
presence of stromal cells
To determine whether m15-IgG1 could induce cell death
in presence of stromal cells, CLL-B cells were cultured
with stroma-NK-tert cells in presence of increasing
concentrations of m15-IgG1 and cell death was evaluated
after 48 h. F-ara-A, an agent that inhibits DNA synthesis
and is a cornerstone for the treatment for CLL patients
[36] as well as AMD3100, a CXCR4 small molecule
inhibitor [37], were evaluated for comparison. m15-IgG1
induced cell death of leukemia cells cultured either alone
or in presence of stromal cell support (stroma NK-tert
cells), demonstrating the ability of the antibody to induce
cell death in presence of stromal cells (Fig. 3c). Similar
results were observed for various B-CLL patients
(Additional file 3: Figure S3).
Moreover, m15-IgG1 was more potent at inducing cell
death than F-ara-A (p < 0.0001) in CLL-B cells (Fig. 3c).
AMD3100, which binds and inhibits signaling through
CXCR4, did not induce cell death in CLL-B cells
(Fig. 3c), indicating that binding and inhibition of the
CXCR4 pathway is not sufficient to trigger cell death.
Next, we sought to determine whether the Fc constant re-
gion or backbone of the CXCR4 antibody played a role in
the ability to induce B-CLL cell death. We compared m15-
IgG1 to m15-IgG4, which is an antibody with the same
antigen-binding regions from m15-IgG1, cloned in a human
IgG4 constant region. Results from these studies (Additional
file 4: Figure S4) demonstrate that both antibodies are cap-
able to induce cell death in CLL-B cells to similar degrees,
with no significant difference between m15-IgG1 and m15-
IgG4, cultured alone or co-cultured with stroma cell sup-
port (p > 0.05). This indicates that the antibody constant
region does not play a role in this cell death mechanism.
The CXCR4 antibody induces B-CLL cell death independently
of CLL risk factor and spares normal B and T lymphocytes
In addition to the high-risk and low-risk prognosis markers
ZAP70 and IgVH, the 17p deletion in the TP53 gene is also
considered a strong independent adverse prognostic factor
for survival and is associated with the short median
treatment-free survival, in CLL patients with CLL [38].
To evaluate the ability of the CXCR4 antibody to in-
duce cell death in leukemia cells from CLL patients with
high risk (CLL-HR), low risk (CLL-LR), as well as with
TP53 17pDel status, we treated samples from patients
with these various genetic backgrounds with m15-IgG1
and evaluated cell death after 48 h of culture. Similar
levels of cell death were induced by m15-IgG1 in CLL-
LR, CLL-HR, TP53wt, or TP53mut/Del(17p) patient
samples (Fig. 3d). This indicates that low-risk, high-risk, or
Fig. 2 PF-06747143 binds specifically to human CXCR4-expressing cells and blocks CXCL12-induced calcium flux. a CHO-parental and CHO-hCXCR4 cell
lines were exposed to 20 μg/mL of either a human IgG1 ĸ-PE antibody (isotype control) or PF-06747143-PE and analyzed by flow cytometry. b Calcium flux
assay was performed in human T cell leukemia Jurkat cells incubated with PF-06747143, m15-IgG1, or isotype control IgG1 antibody in presence of CXCL12
at 8 nM. Experiment was performed in quadruplicates. Shown are mean intracellular calcium concentrations in relative fluorescence units (RFU). ± standard
error of the mean (SEM)
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TP53 statuses are not factors for sensitivity to m15-IgG1.
Moreover, m15-IgG1-induced cell death was significantly
higher than that with F-ara-A (p < 0.0001), which is known
to be a TP53-dependent chemotherapy agent [39, 40].
F-ara-A did not induce cell death in TP53mut/Del(17p)
even at supra-physiological concentrations (>3 μM).
Importantly, m15-IgG1 induced significantly lower
levels of cell death in normal B and T lymphocytes com-
pared with CLL samples (p < 0.0001) (Fig. 3d). These data
suggest that m15-IgG1-induced cell death is dependent
on the level of CXCR4 expressed in the cells.
To characterize the kinetics of cell death induced by the
CXCR4 antibody, a washout experiment was carried out,
where CLL-B cells were incubated with m15-IgG1
(200 nM) for increasing lengths of time, after which the
antibody was washed out. Readouts were performed 48 h
post-treatment initiation. Cell death was observed as early
as 3 h and continued to increase until 48 h after m15-
IgG1 was removed (Additional file 5: Figure S5). This ef-
fect was also independent of presence of stromal cells.
The CXCR4 antibody synergizes with CLL standard of care
agents
To determine if the CXCR4 antibody could offer add-
itional benefit to available therapies, the m15-IgG1 anti-
body was evaluated in combination with SOC agents
currently used in the treatment of CLL patients in the
clinic. The percent cell death combinatorial effect was
evaluated in both high-risk (HR) and low-risk (LR) CLL
patient cells, in presence or absence of stromal cell sup-
port (Fig. 4). Overall, the presence of stromal cells did not
appear to be a significant factor in the ability of m15-IgG1
to synergize with CLL SOC agents. Rituximab, an anti-
CD20 antibody [41, 42], was tested at 2, 10, and 30 μg/
Fig. 3 CXCR4 antibody-induced cell death is dependent on CXCR4-expression and independent of CLL disease risk factor or stromal presence.
a CXCR4 expression profiling was done using an anti-CXCR4 antibody for staining in the MEC1 cell line and primary CLL-B cells from a representative
patient, followed by analysis using flow cytometry. The CXCR4 expression is presented in ΔMFI. b MEC1 and CLL-B cells were treated with different
concentrations of m15-IgG1 (2–2000 nM) or IgG1 control antibody, for 48 h followed by flow cytometry analysis to determine % SICD. Samples were
tested in duplicates, with the mean and standard deviation shown for each group. c The CLL-B cells derived from a CLL patient were treated with
either F-ara-A (3 and 10 μM), AMD3100 (4 and 40 μM), IgG1 control antibody, or m15-IgG1 antibody, in presence or absence of stroma NK-tert cells, for
48 h followed by analysis using flow cytometry. The results of samples analyzed in duplicates with the mean ± SD are shown for each group. d Primary
leukemia CLL-B cells were obtained from CLL patients, with high-risk or low-risk phenotypes, or carrying TP53 17pDel mutation (n = 10 per group). Nor-
mal B and T lymphocytes were obtained from healthy donors (n = 10 per group). The % SICD was determined after treatment with 100 nM of m15-
IgG1 for 48 h. The figure shows the mean ± SD for % SICD in different cell types. Statistical significance was determined using Bonferroni’s correction
test for multiple comparison tests, where *, **, ***, and **** represent p < 0.05; p < 0.01, p < 0.001, and p < 0.0001, respectively
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mL. Synergistic cell death responses, in the range of 10–
30%, were observed for both low- and high-risk patients,
for all rituximab doses tested (Fig. 4a). Ibrutinib (IBM)
or imbruvica, a BTK inhibitor [43], was tested at 0.1, 10,
and 30 μM, and synergism was observed in 50–60% of
high-risk patients and 50-80% of low-risk patients sam-
ples (Fig. 4b). Bendamustine, a chemotherapy agent
derived from nitrogen mustard, commonly used in the
treatment of CLL and lymphomas [44], was tested at
0.1, 30, and 90 μM. Synergistic effects were noted in
30–70% of high-risk samples and in 50–90% of low-risk
patients (Fig. 4c). F-ara-A was tested at 0.3, 3, and
10 μM doses. Synergistic effects were observed in 30–
60% of high-risk and in 50–70% of low-risk patient
samples (Fig. 4d).
m15-IgG1 and PF-06747143 induce similar CLL cell death
To establish if the humanized IgG1 CXCR4 antibody PF-
06747143 and its parent antibody m15-IgG1 had compar-
able cell death activity, we performed a cell death study in
leukemic B cells derived from B-CLL patient, comparing
both antibodies. As shown in Fig. 5a, activity of both anti-
bodies was very similar, with cell death induced at doses
as low as 10 nM by both antibodies. Both antibodies in-
duced similar degree of cell death, regardless of the pres-
ence of stromal cells.
Intact antibodies possess two binding regions, which
allow for binding to two epitopes at the same time. To de-
termine if binding to two epitopes (bivalency) was re-
quired for PF-06747143 to induce cell death, the following
forms of the PF-06747143 were compared: bivalent full-
Fig. 4 Cell death synergism of m15-IgG1 antibody with components of standard of care (SOC) in CLL. The primary leukemia CLL-B cells were in-
cubated either alone or with stroma-NK-tert cells and treated with m15-IgG1 (200 nM) and three different concentrations of SOC agents a rituxi-
mab (1, 3, and 10 μg/mL), b ibrutinib (0.1, 10, and 30 μM), c bendamustine (0.1, 30, and 90 μM), and d fludarabine (F-ara-A, 1, 3, and 10 μM).
Treatments were performed with each agent alone or in combination. The % cell death was used to calculate the median effect of the com-
binatorial effect of m15-IgG1 with each different SOC agent. The synergism between m15-IgG1 and SOCs was expressed as a combination
index (CI), which uses the definitions: additive (CI = 1), synergistic (CI < 1), and antagonistic (CI > 1). The data were analyzed. The empty
circle symbols (O) denote CLL cells alone, while solid black symbols (■) denote CLL cells co-cultured with stroma-NK-tert cells
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length (PF-06747143 FL), bivalent with no Fc region
(F(ab’)2), and monovalent (Fab) (Fig. 5a). Comparable cell
death (SICD) activity for the F(ab’)2 form of PF-06747143
antibody and the intact antibody (FL) was observed, while
the Fab form of the antibody did not induce cell death.
These results indicate that bivalency, or ability to bind to
two epitopes at once, is required for PF-06747143 ability
to induce cell death.
PF-06747143 induction of cell death is caspase
independent
To determine the mechanism through which PF-
06747143 induced cell death, caspase activation was
evaluated. PF-06747143 treatment of CLL-B cells did
not induce significant activation of caspase 3, 8, and 9 in
CLL-B cells (Additional file 6: Figure S6). In a follow-up
experiment, Z-VAD-FMK (Z-VAD), an irreversible pan-
caspase inhibitor [45, 46], rescued caspase-dependent
apoptosis in CLL-B cells after treatment with etoposide
or F-ara-A, which are both known to induce caspase-
dependent cell death. However, Z-VAD failed to rescue
the CLL-B cells treated with PF-06747143, indicating
that the mechanism of cell death induced by PF-
06747143 is caspase independent (Fig. 5b).
Reactive oxygen species (ROS) production is associated
with PF-06747143-induced cell death
Antibody-induced non-apoptotic cell death in human
lymphoma and leukemia cells had been previously
shown to be mediated through a ROS-dependent path-
way, named programmed cell death (PCD) [32]. This
novel cell death mechanism does not rely on caspase
activation and is dependent on homotypic cell adhesion
triggered upon antibody binding, followed by actin
Fig. 5 PF-06747143-induced cell death is bivalency-dependent, involves ROS, but not caspase activation. a Primary leukemia B cells obtained from a CLL
patient were cultured alone or in presence of stroma-NK-tert cells after treatment with 10, 100, and 1000 nM of m15-IgG1, PF-06747143, or its Fab and
F(ab’)2 forms, for 48 h. % SICD was measured by flow cytometry using CD19/CD5/Annexin V staining. The results of samples analyzed in duplicates with
the mean ± SD are shown for each group. b CLL cells were incubated with PF-06747143 (100 nM), F-ara-A (10 μM), or etoposide (30 μM) for 48 h, either
alone or in combination with different concentrations of a pan-caspase inhibitor, Z-VAD-FMK (Z-VAD) (10, 30, 90 μM). CLL cell death was analyzed by flow
cytometry. c CLL-B cells (n= 6 per group) were incubated for 48 h with the intact CXCR4 antibody PF-06747143, the Fab and the F(ab’)2 forms of the anti-
body, the CD20 antibodies rituximab or obinutuzumab, or the IgG1 control antibody. H2O2 was used as a positive control. ROS production and cell dealth
were analyzed by co-staining for ROS and CD19+/CD5+/Annexin V, respectively. The figure shows the individual data points for each group, and horizontal
lines represent the mean of each group. Statistical significance was determined using Bonferroni’s correction test where *, **, ***, and **** represent p<
0.05; p< 0.01, p< 0.001, and p< 0.0001, respectively
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redistribution, lysosome membrane permeabilization,
and ROS activation. Since we showed that PF-06747143
induction of cell death is caspase independent and
bivalency dependent, we hypothesized that PF-06747143
cell death mechanism might involve ROS activation. To
test this hypothesis, CLL-B cells were treated with PF-
06747143 or controls and evaluated for ROS production
after 4 h of treatment. CLL-B cells treated with H2O2,
the positive control, showed high levels of ROS com-
pared to untreated control (****, p < 0.0001), as expected.
Similarly, CLL cells treated with PF-06747143 showed a
rapid increase in cell death and ROS production, com-
pared to the untreated or to the IgG1 control Ab groups
(****, p < 0.0001). Of note, PF-06747143 treated cells had
ROS levels similar to that of the positive antibody con-
trol obinutuzumab (p > 0.05), which has been reported
to induce PCD associated with increased ROS levels
[32]. Rituximab and F-ara-A, which are not known to
induce PCD, did not show a significant increase in ROS
(Fig. 5c).
To determine if binding to two epitopes (bivalency)
was required for PF-06747143 ability to induce cell
death via ROS production, the bivalent full-length
(FL), the bivalent deprived of Fc region (F(ab’)2), and
the monovalent (Fab) forms of the antibody were
evaluated. Comparable ROS activity was observed for
the F(ab’)2 form of PF-06747143 antibody and the
intact antibody (FL), while the Fab form did not
induce cell death or ROS production (Fig. 5c). These
results indicate that bivalency, or ability to bind to
two epitopes at once, is required for PF-06747143 to
induce cell death via a mechanism that involves ROS
induction.
PF-06747143 inhibits F-actin polymerization in CLL cells
Actin polymerization, or cytoskeletal reorganization, is a
surrogate marker of cancer cell migration and metastatic
potential, induced by the interaction of CXCR4 with
CXCL12 [47]. Therefore, we sought to characterize PF-
06747143 role in CXCL12-induced actin polymerization in
CLL-B cells. Stimulation with CXCL12 induced an average
increase in actin polymerization of 450%, relative to base-
line (100%) (Fig. 6a). PF-06747143 significantly inhibited
actin polymerization in a dose response-dependent manner.
PF-06747143 at 100 and 1000 nM inhibited CXCL12-
induced F-actin polymerization to levels below baseline at
85% and 75%, respectively (****, p < 0.0001). The small mol-
ecule inhibitor of CXCR4, AMD3100, was less potent than
PF-06747143 in this assay, with very limited activity at
4 μM, which is its clinically relevant dose. At 40 μM, it
showed moderate inhibition of 180%, which was similar to
the inhibition observed at the lowest dose of PF-06747143
(10 nM) (Fig. 6a).
PF-06747143 inhibits migration of CLL patient-derived
cells
Since PF-06747143 was shown to be a potent inhibitor of
cytoskeletal organization, we evaluated its ability to inhibit
CLL-B cell migration driven by its ligand, CXCL12, using a
transwell migration assay. CXCL12 induced chemotaxis of
CLL-B cells, with an average increase >500% over baseline
(Fig. 6b). PF-06747143 (10 nM–1 μM) significantly inhib-
ited cell migration in a range from 40 to 80%, relative to
CXCL12 induction only (****, p < 0.0001). The effect was
dose dependent. CLL-B cells treated with AMD3100
(40 μM) had similar migration inhibition activity as PF-
06747143 lowest dose (10 nM), but no significant effect
was observed with AMD3100 at 4 μM (Fig. 6b).
PF-06747143 induced CLL cell death via Fc region-mediated
cytotoxicity (ADCC and CDC)
Therapeutic antibodies may rely on their constant region
(Fc domain) ability to induce target cell killing via immune-
mediated effector functions, such as ADCC and CDC to
achieve efficacy. Human IgG1 and IgG3 antibodies have Fc
domain sequences that can mediate potent effector func-
tions, while human IgG4 and IgG2 antibodies display little
or no effector function [48]. PF-06747143 is a humanized
IgG1 antibody; therefore, ADCC and CDC studies were
performed to characterize the antibody Fc-driven cytotoxic
activity on CLL patient cells.
CDC cell death mechanism depends on the interaction
between active serum complement proteins with the Fc
region of the antibody, upon binding to the target cells.
To evaluate if PF-06747143 could induce CDC in CLL-B
cells, it was tested in the presence of active or inactive
serum protein. As shown in Fig. 7a, PF-06747143 signifi-
cantly (p < 0.0001) increased cytotoxicity in presence of
active complement, relative to inactive complement, and
this response was antibody dose dependent.
In the case of ADCC, effector cells bind to the Fc
region of the antibody, when bound to target cells,
and trigger cell lysis. To characterize the Fc-mediated
ADCC activity of PF-06747143, CLL-B cells were in-
cubated with the antibody in presence of effector
cells. Two therapeutic antibodies, rituximab and obi-
nutuzumab, that bind to CD20 and rely on ADCC as
their main mechanism of action were used as positive
controls. As expected, rituximab and obinutuzumab
induced ADCC of CLL-B cells to high levels. PF-
06747143 had comparable ADCC activity to that of
the CD20 antibodies, inducing significant ADCC,
when compared to the negative IgG1 control antibody
(Fig. 7b). Taken together, these data demonstrate that PF-
06747143, a humanized IgG1 antibody, has strong Fc-
driven cytotoxic-dependent activity, leading to elimination
of CLL-B cells.
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To evaluate the role of the human IgG backbone in
the ADCC activity of a CXCR4 antibody, we com-
pared PF-06747143, m15-IgG1, and m15-IgG4, gener-
ated by cloning of the m15 variable domain in a
human IgG4 backbone. The ADCC assay was per-
formed using the CLL tumor cells (JVM-13), in pres-
ence of NK92158V effector cells. The m15-IgG1
antibody showed strong cytotoxicity, when compared
to no activity with the m15-IgG4 antibody (Fig. 7c).
This is in agreement with the expected diminished
ADCC activity of an IgG4 antibody. In addition, PF-
06747143 exerted similar cytotoxicity to that of m15-
IgG1, confirming that the parent antibody (m15-IgG1)
and its humanized antibody (PF-06747143) have com-
parable ADCC functional properties.
PF-06747143 is efficacious as a monotherapy and in
combination with bendamustine in a CLL xenograft
established in vivo model
To determine if PF-06747143 is effective in eliminating
CLL tumor cells in vivo, a disseminated model in which
the tumor cells were implanted intravenously and mi-
grate spontaneously to various sites in the body, includ-
ing the BM and lymph nodes, was used (Fig. 8). Activity
of PF-06747143 was evaluated as a monotherapy as well
as in combination with bendamustine, a SOC agent ap-
proved for CLL treatment. Bioluminescence imaging
performed on day 26 showed that PF-06747143 treat-
ment as a monotherapy decreased tumor burden com-
pared to hIgG1 control Ab and bendamustine groups. A
combinatorial effect was observed when PF-06747143
Fig. 6 PF-06747143 inhibits CXCL12-induced tumor cell actin polymerization and migration. a B-CLL patient cells were treated with no
compound (negative control), AMD3100 (4 and 40 μM), or PF-06747143 (10, 100, and 1000 nM) prior to stimulation with CXCL12 (90 nM)
for 15 s. F-actin polymerization was measured using FITC-labeled phalloidin in CD19/CD5-pre-labeled CLL patient cells. All samples are
plotted relative to the mean fluorescence intensity of the negative control group, without chemokine CXCL12, set to 100%. The results of
samples analyzed in duplicates with the mean ± SD are shown for each group. b CLL patient primary cells were incubated with PF-
06747143 (10, 100, 1000 nM) or AMD3100 (4 and 40 μM) for 1 h and loaded onto a transwell chamber and incubated for 2 h in the
presence of CXCL12 (12 nM) or media control. Cells that migrated to the lower chamber were enumerated using flow cytometry. The
results of samples analyzed in duplicates with the mean ± SD are shown for each group. Statistical significance was determined using
Bonferroni’s correction test
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was given with bendamustine (Fig. 8a). PF-06747143
strong tumor growth inhibition also resulted in signifi-
cant survival benefit at the end of the study, day 75. The
hIgG1 negative control Ab and bendamustine groups
had median survival of 27 and 40 days, respectively,
while PF-06747143 monotherapy group lived signifi-
cantly longer, with median survival of 68.5 days (p <
0.0001 vs IgG1 control Ab and p < 0.0094 vs bendamus-
tine) (Fig. 8b). The median survival for the PF-06747143
and bendamustine combination group was not reached
by the last day of the study (day 75), demonstrating a
combinatorial effect between these two agents. Taken to-
gether, these results show that PF-06747143 reduces BM
and lymph node tumor burden and improves survival, as
a monotherapy in a CLL disseminated tumor model.
Moreover, its efficacy is improved in combination with
bendamustine.
Discussion
CXCR4 overexpression was shown to correlate with poor
prognosis in CLL patients [23]. Activation of CXCR4 in-
duces cell trafficking and homing of malignant cells to the
BM and lymph nodes [49, 50], where CXCL12 is highly
expressed, leading to retention of these cells in a micro-
environment that provides growth signals, induces prolif-
eration, and contributes to drug resistance, leading to
poor prognosis and relapse [51]. In this study, we assessed
the effect of inhibition of the CXCR4-CXCL12 pathway by
a novel CXCR4 antagonist IgG1 antibody, PF-06747143,
and its parental antibody m15-IgG1.
We showed that the surface expression of CXCR4 is at
least tenfold higher in CLL patients than in normal T and
B cells, in concordance with previous studies [52–54].
Similar CXCR4 expression levels were observed in high-
risk or low-risk prognostic CLL patients. Importantly,
both CLL risk groups had comparable sensitivity to
CXCR4 antibody-induced cell death, while normal T and
B cells, or the CXCR4-negative MEC-1 cell line, were
largely spared. This indicates that the cell death mechan-
ism is dependent on the level of CXCR4 surface expres-
sion. Notably, cells from CLL patients bearing the
TP53mut/Del(17p) genotype, which is known to be
Fig. 7 PF-06747143 induces CLL-B cell killing by ADCC and CDC. a CDC assay was performed by treating CLL-B cells (1 × 106/mL) with PF-06747143, in
presence of complete or heat-inactivated 5% human serum. The cells were incubated for 4 h and the cytotoxicity was determined using flow cytometry
with CD19/CD5/Annexin V staining. b The ADCC assay in patient B-CLL cells was performed using 1:1 ratio of the target/effector cell (T/E) and incubated
for 6 h at 37 °C. The IgG1 control antibody, PF-06747143, and rituximab were tested in a 1:3 titration curve, ADCC activity was determined using Bio-Glo™
luciferase assay, and the luminescence results are expressed in relative light units (RLU). The samples were analyzed in duplicates with the mean and SD
shown for each group. The data was analyzed using Prism 4 GraphPad software. c ADCC activity was evaluated in JVM-13 tumor cells by incubating the
cells with PF-06747143, m15-IgG1, m15-IgG4, or respective negative control antibodies for 4 h, in the presence of NK92 158V effector killer cells (effector/tar-
get cell ratio 10:1). Cell lysis was measured by ToxiLight bioluminescent cytotoxicity assay. Experiments were performed in quadruplicates with the mean ±
SEM shown for each group
a
b
Fig. 8 PF-06747143 inhibits tumor burden and increases survival as a
monotherapy or in combination with bendamustine, in a disseminated
CLL tumor model. JVM-13-Luc CLL cells were implanted intravenously
(1 × 106 cells) and allowed to spontaneously migrate and home in the
bone marrow and lymph nodes for 19 days, when animals were
randomized (n = 10/group). Animals were treated with IgG1 control or
PF-06747143 antibodies at 10 mg/kg, subcutaneously, weekly, for
six doses. Bendamustine was dosed at 30 mg/kg, intraperitoneally, on
days 19 and 20, followed by another 2-day cycle 28 days later a Whole-
body bioluminescence representative imaging showing bone marrow
tumor burden on day 26. b Kaplan-Meier survival curve, using hind leg
paralysis as endpoint
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resistant to F-ara-A therapy, were significantly sensitive to
cell death induced by CXCR4 antibody treatment. This is
of particular relevance in the treatment of refractory pa-
tients, who, in general, present with abnormal TP53 status
[55]. Furthermore, the similar levels of cell death observed
in CLL-B cells cultured in presence or absence of stromal
cell support suggest that the CXCR4 antibody has the po-
tential to overcome the protection provided by the micro-
environment. These findings may have significant clinical
implications in the treatment of patients presenting with
minimal residual disease in the BM and lymph nodes.
The CXCR4 antibody significantly synergized with CLL
SOC agents (rituximab, ibrutinib, F-ara-A, and bendamus-
tine), by increasing CLL cell death. Furthermore, we
demonstrated that PF-06747143 improves survival as a
monotherapy and its activity is increased when combined
with bendamustine in the JVM-13 mouse xenograft
disseminated staged model. These findings illustrate the
potential of PF-06747143 to be used in combination with
these agents in the clinic.
PF-06747143 blocked CXCL12-induced cytoskeletal
changes and migration of primary CLL-B cells. Although
to a lesser extent, these events were also inhibited by
AMD3100, the CXCR4 small molecule inhibitor. How-
ever, the lack of cell death activity shown by ADM3100
in this study, and by CXCR4 peptide inhibitors described
in the literature [4, 53, 56], suggests that just binding to
CXCR4 and inhibiting CXCR4 signaling pathways is not
sufficient to trigger this phenomenon. These differences
may be explained by the observation that PF-06747143
induction of cell death required antibody bivalency.
Bivalent binding is a property inherent to antibodies,
due to their two binding regions, which are not a
characteristic of small molecules or peptides. Other anti-
CXCR4 antibodies, including ulocuplumab, LY2624587,
and hz515H7, were also shown to induce tumor cell
death upon binding to CXCR4 [23, 46, 57]; however, the
role of antibody bivalency in this process was not
described in these studies.
In further characterizing the mechanisms involved in
the cell death triggered by PF-06747143, we demon-
strated that this process did not involve caspase activa-
tion. The PF-06747143 caspase-independent cell death
mechanism is similar to that described for ulocuplumab,
an IgG4 CXCR4 antibody [46].
Recently, antibodies binding to CD20, CD74, CD47, or
HLA-DR have been shown to directly induce programmed
cell death (PCD), without involvement of caspases or the
need for hyper-cross-linking of the antibody [32, 58]. This
novel cell death mechanism is dependent on homotypic cell
adhesion triggered upon antibody binding, followed by
actin redistribution and ROS activation [59, 60]. Although
it remains unclear which proximal events trigger PCD, the
process results in loss of plasma membrane integrity and
non-apoptotic cell death. A role for antibody bivalency in
PCD has not been previously described; however, our re-
sults suggest that antibody bivalency might play a role in
the initiating steps, by inducing homotypic cell-cell adhe-
sion through binding to antigens expressed in adjacent cells
simultaneously. We have also shown that PF-06747143
treatment generated ROS production in CLL-B cells, in as-
sociation with cell death. The pattern of ROS production
and cell death induced by PF-06747143 was similar to that
observed with other antibodies shown to induce ROS-
dependent cell death, such as CD20 (obinutuzumab), TAG-
A1 [61], and 1D10 [62]. Taken together, our results suggest
that upon binding to CXCR4 receptors in a bivalent man-
ner, PF-06747143 triggers cell death through a caspase-
independent and bivalency-dependent mechanism, similar
to PCD.
In addition to signaling blockade and induction of
bivalency-dependent cell death, PF-06747143 showed po-
tent Fc effector-mediated ADCC and CDC activity in
CLL-B cells. Of note, PF-06747143 and m15-IgG1 ADCC
activity was significantly greater than that of the m15-
IgG4 antibody in the ADCC assay. Similarly to m15-IgG4,
ulocuplumab, which is a human IgG4 CXCR4 antibody,
was recently reported to have no Fc-driven cytotoxic activ-
ity [46, 57]. The lack of Fc effector function-driven cyto-
toxicity observed for the IgG4 antibodies is expected,
based on the human IgG4 inherently lower affinity for the
proteins involved in the process [63]. We also showed that
PF-06747143 cytotoxic activity was comparable to that of
obinutuzumab and rituximab [64]. The importance of
ADCC or CDC activity has been clinically demonstrated
for obinutuzumab and rituximab, as well as other anti-
bodies successful therapeutic IgG1 antibodies approved
for the treatment of cancers, including alemtuzumab
(CD52), trastuzumab (HER2), cetuximab (EGFR), and dar-
atumumab (CD38) [48, 65].
Therapeutic CXCR4 antagonists currently available
lack desirable potency, cytotoxicity, safety, or adequate
exposure for prolonged treatment. The small molecule
AMD3100 approved for stem cell mobilization in au-
tologous transplantation has significant safety issues
that limit its chronic use [16]. In addition, we showed
that AMD3100 does not induce significant cell death in
B-CLL cells. Peptide antagonists of CXCR4 have been
recently evaluated in clinical trials as mobilizing agents.
LY2510924 was evaluated as a single agent in a phase 1
dose escalation trial in advanced metastatic cancers
[66], and BKT140 (BL8040/TN14003) was evaluated in
a phase 1 clinical trial in multiple myeloma (MM) pa-
tients [19]. Treatment with both peptides induced rapid
mobilization of stem cells but failed to reduce tumor
burden. In addition, as for peptide therapeutics in gen-
eral, they had short half-lives and required frequent
administration, which makes peptides a challenging
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modality for sustained treatment [19, 66, 67]. The
CXCR4 antagonist humanized IgG4 antibody, ulocuplu-
mab, was recently evaluated in phase 1 clinical trials
[20–22] and, as expected for an antibody, it exhibited a
longer half-life than that of small molecules and pep-
tides. In contrast to small molecule and peptide inhibi-
tors of CXCR4, ulocuplumab, as well as another IgG4
CXCR4 antibody, LY26245587, and an IgG1 CXCR4
antibody hz515H7 [68], can induce tumor cell death via
a mechanism reminiscent of PCD, similarly to PF-
06747143.
However, the IgG4 antibodies do not induce tumor
cell death via ADCC or CDC [23, 46], as expected for
human IgG4 antibodies. PF-06747143 and hz515H7 are
the first IgG1 CXCR4 antibodies to be described. A key
role for Fc effector functions ADCC and CDC was dem-
onstrated when a mutation in the Fc region of hz515H7,
abrogating the Fc effector function, resulted in signifi-
cantly decreased efficacy in a mouse tumor model [68].
Taken together, these data suggest that the CXCR4 anti-
body Fc effector cytotoxic functions, ADCC and CDC,
play a key role in vivo and they may contribute to
efficacy enhancement in the clinic.
Conclusions
The novel CXCR4 antagonist IgG1 antibody PF-
06747143 binds to CXCR4 with high affinity and blocks
CXCL12-induced mechanisms including calcium flux
and cell migration. The CXCR4 antibody mediates CLL-
B cell death via a bivalency-dependent mechanism,
involving generation of reactive oxygen species (ROS),
with no caspase activation requirement, reminiscent of
PCD. Moreover, PF-06747143 induces B-CLL cell death
regardless of patient prognostic risk factor or the pres-
ence of stromal cells, indicating that it may be valuable
in the treatment of resistant disease. PF-06747143 syner-
gizes with CLL SOC agents such as bendamustine, ritux-
imab, fludarabine, and ibrutinib. Moreover, in a CLL
xenograft tumor model, PF-06747143 causes tumor
growth inhibition, with increased survival, both as a
monotherapy and in combination with bendamustine.
Differently from other CXCR4 antagonists in the clinic,
PF-06747143 induces potent cell death via Fc-driven
cytotoxicity, through ADCC and CDC. Taken together,
our data support the development of PF-06747143 for
the treatment of CLL patients.
Additional files
Additional file 1: Figure S1. CXCR4 expression profiling in different cell
lines. CXCR4 expression was performed using the 2B11 CXCR4 antibody
clone for surface staining of MEC1, K562, Raji, Ramos, Jurkat, Namalwa,
and JeKo-1 cell lines followed by analysis of samples using flow cytometry.
The CXCR4 expression is presented as ΔMFI. (PDF 528 kb)
Additional file 2: Figure S2. PF-06747143 and its Fab and F(ab’)2 forms
block CXCL12-induced calcium flux. The calcium flux assay was performed in
human T cell leukemia Jurkat cells incubated with PF-06747143 full-length (FL),
PF-06747143-Fab, PF-06747143 F(ab’)2, or isotype control IgG1 antibody in
presence of CXCL12 at 8 nM. For adequate comparison between the different
forms of the antibody, their concentrations were adjusted relative to their
antigen-binding site numbers. Experiment was performed in quadruplicates.
The mean intracellular calcium concentration is shown in relative fluorescence
units (RFU). Bars denote standard error of the mean (SEM). (PDF 389 kb)
Additional file 3: Figure S3. The PF-06747143 parent IgG1 antibody (m15
IgG1) induces cell death and this activity is similar in HR and LR CLL patients.
Primary CLL-B cells derived from CLL patients were incubated either alone
(n = 10) or co-cultured with stroma-NK-tert cells (n = 10) and treated with
vehicle, IgG1 control Ab, or m15-IgG1 antibody for 48 h. Cell death was
measured using CD19/CD5/Annexin V staining followed by flow cytometry
analysis. The data is derived from five high-risk (HR) and five low-risk (LR)
CLL patients. The HR patients are presented with solid symbols (•) and LR
patients denoted with hollow symbols (○). The individual data points for
each group are shown. The horizontal lines represent the mean for each
group Statistical comparisons were performed using Bonferroni’s correction
test. (PDF 744 kb)
Additional file 4: Figure S4. m15-IgG1 and m15-IgG4 have similar cell
death activity in HR and LR CLL patients, in presence or absence of stromal
cells. The primary CLL-B cells derived from CLL patients were incubated either
alone (n= 4) or co-cultured with stroma-NK-tert cells (n= 4) and treated with
vehicle, m15-IgG1, m15-IgG4, IgG1 control antibody, or IgG4 control antibody
for 48 h. Cell death was measured using CD19/CD5/Annexin V staining
followed by flow cytometry analysis. The data is presented as % specific in-
duced cell death (% SICD). The data shown is derived from two high-risk (HR)
and two low-risk (LR) CLL patients. The HR patients are presented with solid
symbols (•) and LR patients denoted with hollow symbols (○). The individual
data points for each group are shown. The horizontal lines represent
the mean for each group. Statistical comparisons were performed
using Bonferroni’s correction test. (PDF 1032 kb)
Additional file 5: Figure S5. The CXCR4 antibody-induced CLL cell death
increases over time, in presence or absence of stromal cells. In this washout
experiment, patient CLL cells cultured alone or in presence of stroma-NK-tert
cells and were treated with vehicle or m15-IgG1 antibody (200 nM) for 0.5, 2,
6, 12, 24, 36, and 48 h. Cell death was measured using CD19/CD5/Annexin V
staining followed by flow cytometry analysis. The samples were tested in du-
plicates. Statistical comparisons were performed using Bonferroni’s correction
test. (PDF 513 kb)
Additional file 6: Figure S6. m15-IgG1-induced LR or HR CLL-B cell
death is independent of caspase activation. CLL-B cells were treated for
6 h with m15-IgG1 (1, 10, or 100 nM) or IgG1 control antibody. Caspases
3, 8, and 9 were measured using a colometric detection method. The
data shown is derived from four high-risk (HR) and four low-risk (LR) CLL
patients. The HR patients are denoted by triangles and LR patients denoted by
circles. The individual data points for each group are shown. The horizontal
lines represent the mean for each group. Statistical comparisons were
performed using Bonferroni’s correction test. (PDF 915 kb)
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